Therapeutic potential of MEK inhibition in acute myelogenous leukemia: Rationale for "vertical" and "lateral" combination strategies

Journal of Molecular Medicine

Volumn 90, Issue 10, 2012, Pages 1133-1144

  Ricciardi, Maria Rosaria ^a   Scerpa, Maria Cristina ^a   Bergamo, Paola ^b   Ciuffreda, Ludovica ^b   Petrucci, Maria Teresa ^a   Chiaretti, Sabina ^a   Tavolaro, Simona ^a   Mascolo, Maria Grazia ^a   Abrams, Stephen L ^c   Steelman, Linda S ^c   Tsao, Twee ^d   Marchetti, Antonio ^e   Konopleva, Marina ^d   Del Bufalo, Donatella ^b   Cognetti, Francesco ^b   Foà, Robin ^a   Andreeff, Michael ^d   McCubrey, James A ^c   Tafuri, Agostino ^a   Milella, Michele ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c EAST CAROLINA UNIVERSITY   (United States)

^d UNIVERSITY OF TEXAS   (United States)

^e UNIVERSITY OF CHIETI   (Italy)

Author keywords

Combinations; Hematological malignancies; MAPK; Resistance; Sensitivity; Synergism

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PROTEIN KINASE B; PROTEIN P70; RAF PROTEIN; SORAFENIB; TEMSIROLIMUS;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; UPREGULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZAMIDES; BENZENESULFONATES; CELL PROLIFERATION; CELL SURVIVAL; DIPHENYLAMINE; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; INHIBITORY CONCENTRATION 50; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKEMIA, MYELOID, ACUTE; MAP KINASE KINASE 1; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-RAF; PYRIDINES; SIGNAL TRANSDUCTION; TRANSCRIPTOME; TUMOR CELLS, CULTURED;

EID: 84867328500     PISSN: 09462716     EISSN: 14321440     Source Type: Journal    
DOI: 10.1007/s00109-012-0886-z     Document Type: Article

References (34)

1. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A et al (2007) Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773:1263-1284
2. Sebolt-Leopold JS, Herrera R (2004) Targeting the mitogenactivated protein kinase cascade to treat cancer. Nat Rev Cancer 4:937-947
3. Gregorj C, Ricciardi MR, Petrucci MT, Scerpa MC, De Cave F, Fazi P, Vignetti M, Vitale A, Mancini M, Cimino G et al (2007) ERK1/2 phosphorylation is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. Blood 109:5473-5476
4. Kornblau SM, Womble M, Qiu YH, Jackson CE, Chen W, Konopleva M, Estey EH, Andreeff M (2006) Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. Blood 108:2358-2365
5. Milella M, Precupanu CM, Gregorj C, Ricciardi MR, Petrucci MT, Kornblau SM, Tafuri A, Andreeff M (2005) Beyond single pathway inhibition: MEK inhibitors as a platform for the development of pharmacological combinations with synergistic anti-leukemic effects. Curr Pharm Des 11:2779-2795
6. Lauchle JO, Kim D, Le DT, Akagi K, Crone M, Krisman K, Warner K, Bonifas JM, Li Q, Coakley KM et al (2009) Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras. Nature 461:411-414
7. Milella M, Kornblau SM, Estrov Z, Carter BZ, Lapillonne H, Harris D, Konopleva M, Zhao S, Estey E, Andreeff M (2001) Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest 108:851-859
8. Milella M, Estrov Z, Kornblau SM, Carter BZ, Konopleva M, Tari A, Schober WD, Harris D, Leysath CE, Lopez-Berestein G et al (2002) Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia. Blood 99:3461-3464
9. Milella M, Konopleva M, Precupanu CM, Tabe Y, Ricciardi MR, Gregorj C, Collins SJ, Carter BZ, D'Angelo C, Petrucci MT et al (2007) MEK blockade converts AML differentiating response to retinoids into extensive apoptosis. Blood 109:2121-2129
10. Lunghi P, Costanzo A, Salvatore L, Noguera N, Mazzera L, Tabilio A, Lo-Coco F, Levrero M, Bonati A (2006) MEK1 inhibition sensitizes primary acute myelogenous leukemia to arsenic trioxide-induced apoptosis. Blood 107:4549-4553
11. Lunghi P, Giuliani N, Mazzera L, Lombardi G, Ricca M, Corradi A, Cantoni AM, Salvatore L, Riccioni R, Costanzo A et al (2008) Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways. Blood 112:2450-2462
12. Tortora G, Bianco R, Daniele G, Ciardiello F, McCubrey JA, Ricciardi MR, Ciuffreda L, Cognetti F, Tafuri A, Milella M (2007) Overcoming resistance to molecularly targeted anticancer therapies: rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies. Drug Resist Updat 10:81-100
13. McCubrey JA, Steelman LS, Abrams SL, Bertrand FE, Ludwig DE, Basecke J, Libra M, Stivala F, Milella M, Tafuri A et al (2008) Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. Leukemia 22:708-722
14. McCubrey JA, Milella M, Tafuri A, Martelli AM, Lunghi P, Bonati A, Cervello M, Lee JT, Steelman LS (2008) Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors. Curr Opin Investig Drugs 9:614-630
15. Lyubynska N, Gorman MF, Lauchle JO, Hong WX, Akutagawa JK, Shannon K, Braun BS (2011) A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice. Sci Transl Med 3:76ra27
16. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27-55
17. Blalock WL, Pearce M, Steelman LS, Franklin RA, McCarthy SA, Cherwinski H, McMahon M, McCubrey JA (2000) A conditionallyactive form of MEK1 results in autocrine tranformation of human and mouse hematopoietic cells. Oncogene 19:526-536
18. Tai YT, Fulciniti M, Hideshima T, Song W, Leiba M, Li XF, Rumizen M, Burger P, Morrison A, Podar K et al (2007) Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis. Blood 110:1656-1663
19. Annunziata CM, Hernandez L, Davis RE, Zingone A, Lamy L, Lam LT, Hurt EM, Shaffer AL, Kuehl WM, Staudt LM (2011) A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression. Blood 117:2396-2404
20. Chambard JC, Lefloch R, Pouyssegur J, Lenormand P (2007) ERK implication in cell cycle regulation. Biochim Biophys Acta 1773:1299-1310
21. Ciuffreda L, Del Bufalo D, Desideri M, Di Sanza C, Stoppacciaro A, Ricciardi MR, Chiaretti S, Tavolaro S, Benassi B, Bellacosa A et al (2009) Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations. Neoplasia 11:720-731
22. Milella M, Chiaretti S, Ricciardi MR et al (2007) Comparative gene profiling of acute myeloid leukemia (AML) and malignant melanoma (MEL) cell lines exposed to the MEK inhibitor PD0325901 reveals common effectors of the MEK/ERK kinase module. Blood 110:3470, ASH Annual Meeting Abstracts
23. Dry JR, Pavey S, Pratilas CA, Harbron C, Runswick S, Hodgson D, Chresta C, McCormack R, Byrne N, Cockerill M et al (2010) Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244). Cancer Res 70:2264-2273
24. Wang D, Boerner SA, Winkler JD, LoRusso PM (2007) Clinical experience of MEK inhibitors in cancer therapy. Biochim Biophys Acta 1773:1248-1255
25. Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, Ye Q, Lobo JM, She Y, Osman I et al (2006) BRAF mutation predicts sensitivity to MEK inhibition. Nature 439:358-362
26. Friday BB, Yu C, Dy GK, Smith PD, Wang L, Thibodeau SN, Adjei AA (2008) BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signalregulated kinase and Raf proteins. Cancer Res 68:6145-6153
27. Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR (1995) PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem 270:27489-27494
28. McKay MM, Ritt DA, Morrison DK (2009) Signaling dynamics of the KSR1 scaffold complex. Proc Natl Acad Sci USA 106:11022-11027
29. Nguyen TK, Jordan N, Friedberg J, Fisher RI, Dent P, Grant S (2010) Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosis. Leuk Res 34:379-386
30. Ou DL, Shen YC, Liang JD, Liou JY, Yu SL, Fan HH, Wang DS, Lu YS, Hsu C, Cheng AL (2009) Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogenactivated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma. Clin Cancer Res 15:5820-5828
31. Ciuffreda L, McCubrey JA, Milella M (2009) Signaling intermediates (PI3K/PTEN/AKT/mTOR and RAF/MEK/ERK pathways) as therapeutic targets for anti-cancer and anti-angiogenesis treatments. Curr Signal Transduct Ther 4:130-143
32. Gopal YN, Deng W, Woodman SE, Komurov K, Ram P, Smith PD, Davies MA (2010) Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. Cancer Res 70:8736-8747
33. Ciuffreda L, Di Sanza C, Cesta Incani U, Eramo A, Desideri M, Biagioni F, Passeri D, Falcone I, Sette G, Bergamo P et al. (2012) The mitogen-activated protein kinase (MAPK) cascade controls phosphatase and tensin homolog (PTEN) expression through multiple mechanisms. J Mol Med (Berl) doi:10.1007/s00109-011- 0844-1
34. Ravandi F, Pigneux A, DeAngelo DJ, Dombret H, Delaunay J, Thomas X, Kadia T, Luepfert C, Asatiani E, Donica M et al (2011) Preliminary clinical, pharmacokinetic (PK) and pharmacodynamic (PD) results of the safety run-in part of a phase II trial of orally available MEK-inhibitor MSC1936369 in patients (Pts) with advanced hematological malignancies (HM). Blood 118:1554 (ASH Annual Meeting Abstracts)